BG-A3004

BG-A3004 is an investigational monoclonal antibody developed by BeOne Medicines for the treatment of various immune-mediated skin diseases. It specifically targets the Interleukin-15 (IL-15) pathway, which is a key driver in the pathogenesis of conditions like alopecia areata and vitiligo. IL-15 is essential for the activation, proliferation, and survival of memory CD8+ T cells; in these autoimmune conditions, these T cells inappropriately attack hair follicles or melanocytes. By neutralizing IL-15 or its signaling, BG-A3004 aims to deplete or deactivate these pathogenic T cells, thereby reducing inflammation and allowing for tissue regeneration. The drug is currently being evaluated in a Phase 1 first-in-human clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy participants and patients with alopecia areata, cutaneous lichen planus, and nonsegmental vitiligo.